Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment

Gut. 2015 Dec;64(12):1921-35. doi: 10.1136/gutjnl-2014-308935. Epub 2015 Apr 3.

Abstract

Objectives: The tumour stroma/microenvironment not only provides structural support for tumour development, but more importantly it provides cues to cancer stem cells (CSCs) that regulate their self-renewal and metastatic potential. This is certainly true for pancreatic ductal adenocarcinomas (PDAC), where tumour-associated fibroblasts, pancreatic stellate cells and immune cells create an abundant paracrine niche for CSCs via microenvironment-secreted factors. Thus understanding the role that tumour stroma cells play in PDAC development and CSC biology is of utmost importance.

Design: Microarray analyses, tumour microarray immunohistochemical assays, in vitro co-culture experiments, recombinant protein treatment approaches and in vivo intervention studies were performed to understand the role that the immunomodulatory cationic antimicrobial peptide 18/LL-37 (hCAP-18/LL-37) plays in PDAC biology.

Results: We found that hCAP-18/LL-37 was strongly expressed in the stroma of advanced primary and secondary PDAC tumours and is secreted by immune cells of the stroma (eg, tumour-associated macrophages) in response to tumour growth factor-β1 and particularly CSC-secreted Nodal/ActivinA. Treatment of pancreatic CSCs with recombinant LL-37 increased pluripotency-associated gene expression, self-renewal, invasion and tumourigenicity via formyl peptide receptor 2 (FPR2)- and P2X purinoceptor 7 receptor (P2X7R)-dependent mechanisms, which could be reversed by inhibiting these receptors. Importantly, in a genetically engineered mouse model of K-Ras-driven pancreatic tumourigenesis, we also showed that tumour formation was inhibited by either reconstituting these mice with bone marrow from cathelicidin-related antimicrobial peptide (ie, murine homologue of hCAP-18/LL-37) knockout mice or by pharmacologically inhibiting FPR2 and P2X7R.

Conclusions: Thus, hCAP-18/LL-37 represents a previously unrecognised PDAC microenvironment factor that plays a critical role in pancreatic CSC-mediated tumourigenesis.

Keywords: ANTIBACTERIAL PEPTIDE; MACROPHAGES; PANCREATIC CANCER; STEM CELLS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activins / metabolism
  • Animals
  • Antimicrobial Cationic Peptides / metabolism*
  • Antimicrobial Cationic Peptides / pharmacology
  • Carcinogenesis / drug effects
  • Carcinogenesis / genetics
  • Carcinogenesis / metabolism
  • Carcinoma, Pancreatic Ductal / genetics
  • Carcinoma, Pancreatic Ductal / metabolism*
  • Carcinoma, Pancreatic Ductal / pathology*
  • Cathelicidins
  • Cell Self Renewal / drug effects
  • Gene Expression / drug effects
  • Humans
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Mice
  • Mice, Nude
  • Neoplasm Invasiveness
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / metabolism*
  • Pancreatic Neoplasms / pathology*
  • Protein Array Analysis
  • Purinergic P2X Receptor Antagonists / pharmacology
  • Receptors, Formyl Peptide / antagonists & inhibitors
  • Receptors, Formyl Peptide / metabolism
  • Receptors, Purinergic P2X7 / metabolism
  • Signal Transduction / drug effects
  • Tissue Array Analysis
  • Transforming Growth Factor beta1 / pharmacology
  • Tumor Microenvironment*

Substances

  • Antimicrobial Cationic Peptides
  • Purinergic P2X Receptor Antagonists
  • Receptors, Formyl Peptide
  • Receptors, Purinergic P2X7
  • Transforming Growth Factor beta1
  • activin A
  • formyl peptide receptor 2, mouse
  • Activins
  • Cathelicidins